Want to see KIDS full AI Analyst Report?
KIDS Stock Chart & Stats
$18.87
$0.95(5.03%)
At close: 4:00 PM EDT
$18.87
$0.95(5.03%)
Day’s Range― - ―
52-Week Range$14.42 - $22.80
Previous Close$20.42
Volume117.04K
Average Volume (3M)196.93K
Market Cap
$518.58M
Enterprise Value$431.30
Total Cash (Recent Filing)$50.86M
Total Debt (Recent Filing)$106.28M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 04, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.68
Shares Outstanding25,684,994
10 Day Avg. Volume194,659
30 Day Avg. Volume196,931
Financial Highlights & Ratios
PEG Ratio-3.45
Price to Book (P/B)1.20
Price to Sales (P/S)1.76
P/FCF Ratio-26.10
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$23.00Price Target Upside21.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.18
Revenue Forecast (FY)$265.24M
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Revenue MomentumSustained ~73% gross margins and strong TTM revenue growth imply durable unit economics for pediatric implants and recurring consumables. High margins provide room to invest in sales and R&D, enabling scalable profitability as adoption, set deployment and ASPs rise across procedures and territories.
Conservative Leverage / Balance-sheet FlexibilityLow debt-to-equity and a strong equity base give the company financial flexibility to fund commercialization and product launches without acute refinancing risk. This capital structure supports multi-quarter execution while management works toward adjusted EBITDA and free-cash-flow breakeven.
Clear Operational Momentum And Regulatory ProgressManagement raised guidance and reported positive adjusted EBITDA in Q1 while securing EU MDR approvals and rolling out multiple beta products. These developments create durable revenue channels (international expansion, higher-ASP launches) and an actionable path to sustained margin and cash-flow improvement.
Bears Say
Ongoing GAAP LossesPersistent GAAP losses and a materially negative TTM net margin constrain internal capital generation and make the company reliant on external financing until profitability is consistently achieved. This reduces flexibility for dividends, buybacks, or aggressive M&A and raises execution pressure.
Negative Cash GenerationDeeply negative operating and free cash flow require continued external funding to support growth and set deployments. Even with year-over-year improvement, sustained negative FCF increases refinancing and dilution risk if product rollouts or revenue realization slow, pressuring long-term sustainability.
Execution & Timing Risks On RolloutsRevenue and margin upside depends on timely set deployments, supply logistics and regulatory clearances; prior lower set deployments and weather-displaced procedures show cadence sensitivity. Delays or constrained set availability could push out ASP and margin benefits and postpone free-cash-flow breakeven.
OrthoPediatrics News
KIDS FAQ
What was OrthoPediatrics Corp’s price range in the past 12 months?
OrthoPediatrics Corp lowest stock price was $14.42 and its highest was $22.80 in the past 12 months.
What is OrthoPediatrics Corp’s market cap?
OrthoPediatrics Corp’s market cap is $518.58M.
When is OrthoPediatrics Corp’s upcoming earnings report date?
OrthoPediatrics Corp’s upcoming earnings report date is Aug 04, 2026 which is in 2 days.
How were OrthoPediatrics Corp’s earnings last quarter?
OrthoPediatrics Corp released its earnings results on Apr 30, 2026. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.455 by $0.005.
Is OrthoPediatrics Corp overvalued?
According to Wall Street analysts OrthoPediatrics Corp’s price is currently Undervalued.
Does OrthoPediatrics Corp pay dividends?
OrthoPediatrics Corp does not currently pay dividends.
What is OrthoPediatrics Corp’s EPS estimate?
OrthoPediatrics Corp’s EPS estimate is -0.3.
How many shares outstanding does OrthoPediatrics Corp have?
OrthoPediatrics Corp has 25,684,994 shares outstanding.
What happened to OrthoPediatrics Corp’s price movement after its last earnings report?
OrthoPediatrics Corp reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.455. Following the earnings report the stock price went up 3.785%.
Which hedge fund is a major shareholder of OrthoPediatrics Corp?
Currently, no hedge funds are holding shares in KIDS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OrthoPediatrics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.00 (21.89% Upside)
$23.00 (21.89% Upside)
Blogger Sentiment
Bullish
KIDS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 254.2K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.79%
Trailing 12-Months
Company Description
OrthoPediatrics Corp
OrthoPediatrics Corp. is a medical technology firm dedicated to the design, development, and global commercialization of specialized implants and devices. These products are meticulously crafted to be anatomically appropriate for treating children affected by orthopedic conditions across the United States and internationally. The company's diverse offerings span products for trauma and deformity correction, surgical systems for spinal deformities such as scoliosis, and solutions for sports medicine, among others. Their comprehensive product line features items like PediLoc, PediPlates, various cannulated screws, the PediFlex and PediNail systems, PediLoc tibia, advanced anterior cruciate ligament reconstruction systems, specialized locking cannulated blades and proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, the Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and the ApiFix Mid-C system. OrthoPediatrics Corp. primarily serves the pediatric orthopedic market, directly assisting pediatric orthopedic surgeons and caregivers. The company was founded in 2006 and maintains its headquarters in Warsaw, Indiana.
KIDS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong execution and acceleration across several strategic fronts: double-digit revenue growth (13% YoY), a return to positive adjusted EBITDA, >20% OPSB growth, international acceleration, multiple promising beta launches (3P Hip, Vertiglyde) and EU MDR approvals. Management raised full-year revenue guidance and reaffirmed a path to adjusted EBITDA of ~$25M and free-cash-flow breakeven in 2026. Key short-term headwinds and risks include weather-related clinic disruptions that shifted some demand into Q2, continued GAAP/non-GAAP net losses, higher operating expense levels, lower set deployments versus prior-year (by design), and timing uncertainty around set availability and product rollouts. On balance, the strategic momentum, margin improvement and guidance raise outweigh the near-term challenges and execution/timing risks.View all KIDS earnings summariesKIDS Stock 12 Month Forecast
Average Price Target
$23.00
▲(21.89% Upside)
Technical Analysis
Orthofix Medical
―
Tandem Diabetes Care
―
Varex Imaging
―
Bioventus
―
Treace Medical Concepts
―
Ownership Overview
33.38% Insiders
13.08% Mutual Funds
3.60% Other Institutional Investors
41.83% Public Companies and
Individual Investors